恒瑞医药：SHR-4375注射液等6种药品获临床试验批准

Core Viewpoint - Heng Rui Medicine announced that it and its subsidiaries have received approval from the National Medical Products Administration for clinical trial notifications for several injectable drugs, indicating a significant step in their drug development pipeline [1] Group 1: Clinical Trial Approvals - The company and its subsidiaries, including Shanghai Heng Rui Medicine Co., Ltd., Shanghai Shengdi Medicine Co., Ltd., and Suzhou Shengdiya Biopharmaceutical Co., Ltd., have received approval for clinical trials of SHR-4375 injection, Adalimumab injection, SHR-8068 injection, Bevacizumab injection, HRS-4642 injection, and SHR-9839 injection [1]